Drug intelligence / Profile preview

LC106 (Zhejiang Longcharm Biomedical Technology Co., Ltd.)

Development stage: Preclinical
Lead developer: Zhejiang Longchuan Biomedical Technology

Overview

LC106 is a preclinical-stage drug candidate being developed by Zhejiang Longcharm Bio-Tech Pharma (Zhejiang Longchuan Biomedical Technology) for the treatment of pancreatic cancer. Currently in the research-to-preclinical phase, the drug's specific molecular target, therapeutic modality, and mechanism of action have not been publicly disclosed. It is part of the company's oncology pipeline, which also includes BTK inhibitors and various drug delivery platforms.

Beyond the preview

Go deeper on LC106 (Zhejiang Longcharm Biomedical Technology Co., Ltd.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LC106 (Zhejiang Longcharm Biomedical Technology Co., Ltd.).

Explore the full profile